Illuminate Diagnostics INC

Illuminate Diagnostics INC was paid $941K by Medicaid between Jun 2022 and May 2024, across 10 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 37% of everything it billed.

Compared with peers

Next to other Clinic/Center providers in California

Rank by total paid#139 of 504

Median peer was paid$102K

This provider vs. median9.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	10,382	$304K
2023	13,112	$544K
2024incomplete	1,202	$93K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	37%	6,937	2,731	$346K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	21%	1,565	836	$199K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	11%	2,104	990	$102K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	10%	6,585	2,670	$97K
87634		8.4%	2,102	992	$79K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	8.2%	2,162	926	$77K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.2%	2,891	1,358	$30K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	1.1%	316	245	$10K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	12	12	$1K
87481		<1%	22	20	$651.99

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKANG, ALEX (MANAGING MEMBER)